Floatz logo

Trastuzumab Deruxtecan

Breast Cancer

SWOG Cancer Research Networkantibody_drug_conjugatePhase 4 / ApprovedActive
BB
66/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
68/ 100
Competitive Position
59/ 100

Competitive context

848 Active assets in the Breast Cancer cohort.

Asset / SponsorPhaseRating
Darolutamide
Vandana Abramson
Phase 2BBB
Pertuzumab
SWOG Cancer Research Network
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
Goserelin
TerSera Therapeutics LLC
Phase 4BB

View all 50 →

Same molecule, other indications

Trastuzumab Deruxtecan is also rated in:

breast carcinomaActive
BBB
Indicative · Phase 4
75 / 100
View asset →
metastatic malignant neoplasm in the brainActive
BB
Indicative · Phase 4
66 / 100
View asset →
triple-negative breast carcinomaActive
BB
Indicative · Phase 2
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →